Acuity Medical Inc.
This article was originally published in Start Up
It's not known how age-related macular degeneration (AMD) converts from the dry, relatively benign form to the wet, sight-threatening form, or in which patients that progression is inevitable. It is known, however, that patients in the early stages face a 1.3 percent risk of developing wet AMD within five years, while people who have advanced to the intermediate stages of dry AMD face an 18% chance of progressing to the sight-threatening advanced dry or wet stages. For this latter group, Acuity Medical hopes to offer a safe, painless, non-invasive vision preserving device therapy for use in the physician's office and home care settings.
You may also be interested in...
Devices for Age-Related Macular Degeneration
The recent FDA approval of The Pfizer/Eyetech drug Macugen, which is expected to yield $350 million in its first year on the market, has focused attention on the opportunity in age-related macular degeneration. But AMD isn't only a pharmaceutical opportunity. AMD is a disease of the retina, in the back of the eye, and that presents delivery problems that devices can solve. Device companies are developing drug delivery implants, device therapies, borrowed from the cardiovascular industry, and new photodynamic therapies that aim to rival Visudyne, QLT's laser-activated drug for wet AMD.
Wound Solutions Ltd.
Wound Solutions Ltd. looks to the paradigm of patient self-care in diabetes to address the gaps in chronic wound care, where the feedback provided by blood glucose monitoring encourages changes in behavior. A small device that is placed under a compression bandage helps patients with venous leg ulcers comply with the steps they should be taking to support wound healing, in the process, collecting data that helps clinicians make informed therapy decisions.
Patient-Centric Devices Promise Cost-Efficient Advanced Wound Care
The treatment of chronic wounds is challenging, not only because of the underlying biology, but also because of more practical considerations: fragmentation in the care settings, the logistics of delivering products to patients, and the costs of chronic care. Next generation advanced wound care companies are engineering solutions to these problems.